Physician profile
Brian Baksa
NPI 1831624352
$4,317.71
in general payments reported to CMS, 2019-2025
35 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.43 · 2022: $348 · 2023: $1,305 · 2024: $1,384 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,658 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,658.26 |
| Education | $255.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $661.20 | 2022-2025 | Carvykti, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $599.61 | 2021-2025 | Opdivo, Reblozyl, Eliquis |
| Daiichi Sankyo INC. | $517.68 | 2022-2025 | Enhertu, Vanflyta |
| Genzyme Corporation | $315.76 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $204.34 | 2024-2025 | Soliris |
| Glaxosmithkline, LLC. | $186.48 | 2023-2025 | Jemperli, Zejula, Shingrix |
| Genentech USA, INC. | $174.51 | 2023-2025 | Lunsumio, Venclexta |
| Incyte Corporation | $173.38 | 2023-2025 | Jakafi, Monjuvi, Jakafi |
| Pfizer INC. | $161.19 | 2021-2025 | |
| Secura Bio, INC. | $122.42 | 2025 | Copiktra |
| Merck Sharp & Dohme LLC | $120.93 | 2022-2025 | Keytruda, Lynparza |
| Seagen INC. | $120.29 | 2023 | Adcetris |
| Amgen INC. | $101.44 | 2021-2024 | Kyprolis, Lumakras, Blincyto |
| Lilly USA, LLC | $90.15 | 2022-2024 | Jaypirca, Retevmo, Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $79.99 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $74.99 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $71.72 | 2023 | Lynparza, Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $67.33 | 2023-2025 | |
| Kerecis Limited | $59.35 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Celgene Corporation | $50.31 | 2023-2025 | Reblozyl |
| Eisai INC. | $45.38 | 2022-2025 | |
| Mirati Therapeutics, INC. | $38.00 | 2024 | Krazati |
| Janssen Pharmaceuticals, INC | $37.49 | 2023 | Xarelto |
| Emd Serono, INC. | $32.43 | 2024-2025 | |
| Genentech, INC. | $29.63 | 2025 | Columvi |
| Caris Mpi, INC. | $26.19 | 2025 | Mi Cancer Seek |
| Immunogen, INC. | $21.13 | 2024 | Elahere |
| Genmab U.S., INC. | $18.13 | 2023 | Tivdak |
| Blueprint Medicines Corporation | $18.03 | 2023 | Ayvakit |
| Taiho Oncology, INC. | $17.90 | 2023 | |
| Geron Corporation | $16.96 | 2025 | Rytelo |
| Abbvie INC. | $16.76 | 2022 | |
| Agios Pharmaceuticals, INC. | $16.18 | 2025 | Pyrukynd |
| Pharmaessentia USA Corporation | $16.04 | 2024 | Besremi |
| Pharmacosmos Therapeutics INC. | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Baksa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.